MX2023004713A - Anticuerpo anti-cd73 y uso del mismo. - Google Patents
Anticuerpo anti-cd73 y uso del mismo.Info
- Publication number
- MX2023004713A MX2023004713A MX2023004713A MX2023004713A MX2023004713A MX 2023004713 A MX2023004713 A MX 2023004713A MX 2023004713 A MX2023004713 A MX 2023004713A MX 2023004713 A MX2023004713 A MX 2023004713A MX 2023004713 A MX2023004713 A MX 2023004713A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- seq
- nos
- amino acid
- chain variable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011152518 | 2020-10-23 | ||
| PCT/CN2021/125564 WO2022083723A1 (zh) | 2020-10-23 | 2021-10-22 | 抗cd73的抗体及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004713A true MX2023004713A (es) | 2023-05-09 |
Family
ID=81291626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004713A MX2023004713A (es) | 2020-10-23 | 2021-10-22 | Anticuerpo anti-cd73 y uso del mismo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240018254A1 (enExample) |
| EP (1) | EP4234579A4 (enExample) |
| JP (1) | JP2023546743A (enExample) |
| KR (1) | KR20230125774A (enExample) |
| CN (2) | CN114478768B (enExample) |
| AU (1) | AU2021363350A1 (enExample) |
| CA (1) | CA3196299A1 (enExample) |
| IL (1) | IL302182A (enExample) |
| MX (1) | MX2023004713A (enExample) |
| WO (1) | WO2022083723A1 (enExample) |
| ZA (1) | ZA202304591B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022002028A2 (pt) * | 2019-08-02 | 2022-04-12 | Cttq Akeso Shanghai Biomed Tech Co Ltd | Anticorpo anti-pd-1 e uso farmacêutico do mesmo |
| WO2023236971A1 (zh) * | 2022-06-08 | 2023-12-14 | 上海华奥泰生物药业股份有限公司 | Cd73抗体鸡尾酒疗法 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN117567613A (zh) * | 2022-12-13 | 2024-02-20 | 华润生物医药有限公司 | 抗cd73抗体及其用途 |
| CN117567615A (zh) * | 2022-12-13 | 2024-02-20 | 华润生物医药有限公司 | 抗cd73抗体及其用途 |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO2016055609A1 (en) * | 2014-10-10 | 2016-04-14 | Innate Pharma | Cd73 blockade |
| RS62003B2 (sr) * | 2014-11-10 | 2025-01-31 | Medimmune Ltd | Vezujući molekuli specifični za cd73 i njihove upotrebe |
| EP3789403A1 (en) * | 2014-11-11 | 2021-03-10 | MedImmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof |
| JP6805142B2 (ja) * | 2014-11-21 | 2020-12-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｄ７３に対する抗体およびその使用 |
| CN104558137A (zh) * | 2015-01-15 | 2015-04-29 | 浙江欧诗漫生物股份有限公司 | 一种珍珠蛋白的制备方法及该方法制备得到的水溶性珍珠蛋白和酸溶性珍珠蛋白 |
| EP3259288B1 (en) * | 2015-02-20 | 2026-07-22 | Innate Pharma | Cd73 blockade |
| WO2017064043A1 (en) * | 2015-10-12 | 2017-04-20 | Innate Pharma | Cd73 blocking agents |
| CA3007646A1 (en) * | 2015-12-09 | 2017-06-15 | Bioatla, Llc | Humanized anti-cd73 antibodies |
| AU2017228470A1 (en) * | 2016-03-04 | 2018-08-30 | Bristol-Myers Squibb Company | Combination therapy with anti-CD73 antibodies |
| CN106967172B (zh) * | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| CA3046432A1 (en) * | 2016-12-13 | 2018-06-21 | Astellas Pharma Inc. | Anti-human cd73 antibody |
| CA3045376C (en) * | 2017-01-24 | 2022-08-30 | I-Mab | Anti-cd73 antibodies and uses thereof |
| WO2018215535A1 (en) * | 2017-05-23 | 2018-11-29 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Novel cd73 antibody, preparation and uses thereof |
| MX2019015885A (es) * | 2017-06-22 | 2020-09-10 | Novartis Ag | Moleculas de anticuerpo que se unen a cd73 y usos de las mismas. |
| AU2019231172B2 (en) * | 2018-03-09 | 2023-08-24 | Phanes Therapeutics, Inc. | Anti-CD73 antibodies and uses thereof |
| CN111434688A (zh) * | 2019-01-11 | 2020-07-21 | 上海开拓者生物医药有限公司 | Cd73抗体及其制备方法和应用 |
| WO2021213466A1 (zh) * | 2020-04-22 | 2021-10-28 | 中山康方生物医药有限公司 | 抗cd73的抗体及其用途 |
| BR112022021426A2 (pt) * | 2020-04-22 | 2022-12-13 | Akeso Biopharma Inc | Anticorpo biespecífico anti-cd73/anti-pd-1, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para preparar o anticorpo biespecífico anti-cd73/anti-pd-1, conjugado, kit, usos do anticorpo biespecífico anti-cd73/anti-pd-1, composição farmacêutica, método in vitro, linhagem celular de hibridoma e anticorpo monoclonal anti-cd73 |
-
2021
- 2021-10-22 JP JP2023548995A patent/JP2023546743A/ja active Pending
- 2021-10-22 WO PCT/CN2021/125564 patent/WO2022083723A1/zh not_active Ceased
- 2021-10-22 CN CN202111237197.7A patent/CN114478768B/zh active Active
- 2021-10-22 IL IL302182A patent/IL302182A/en unknown
- 2021-10-22 AU AU2021363350A patent/AU2021363350A1/en active Pending
- 2021-10-22 KR KR1020237017266A patent/KR20230125774A/ko active Pending
- 2021-10-22 CN CN202510730743.2A patent/CN120590533A/zh active Pending
- 2021-10-22 US US18/250,010 patent/US20240018254A1/en active Pending
- 2021-10-22 EP EP21882137.9A patent/EP4234579A4/en active Pending
- 2021-10-22 MX MX2023004713A patent/MX2023004713A/es unknown
- 2021-10-22 CA CA3196299A patent/CA3196299A1/en active Pending
-
2023
- 2023-04-20 ZA ZA2023/04591A patent/ZA202304591B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL302182A (en) | 2023-06-01 |
| AU2021363350A1 (en) | 2023-06-22 |
| US20240018254A1 (en) | 2024-01-18 |
| JP2023546743A (ja) | 2023-11-07 |
| KR20230125774A (ko) | 2023-08-29 |
| CA3196299A1 (en) | 2022-04-28 |
| WO2022083723A1 (zh) | 2022-04-28 |
| ZA202304591B (en) | 2025-08-27 |
| EP4234579A1 (en) | 2023-08-30 |
| CN114478768B (zh) | 2025-05-30 |
| CN120590533A (zh) | 2025-09-05 |
| CN114478768A (zh) | 2022-05-13 |
| EP4234579A4 (en) | 2025-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202304591B (en) | Anti-cd73 antibody and use thereof | |
| MX2024001067A (es) | Composicion farmaceutica y uso. | |
| ZA202211457B (en) | Anti-cd73 antibody and use thereof | |
| CY1121900T1 (el) | Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2 | |
| CY1114851T1 (el) | Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων | |
| AR117658A2 (es) | Anticuerpos anti-fap y métodos de uso | |
| ES2620264T3 (es) | Anticuerpos humanizados frente a LIV-1 y el uso de los mismos para tratar el cáncer | |
| PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| CO6180445A2 (es) | Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3 | |
| CY1119647T1 (el) | Αντισωματα προσδεσης αλβουμινης και τμηματα προσδεσης αυτων | |
| MX2022001111A (es) | Anticuerpo anti-pd-1 y uso farmaceutico del mismo. | |
| AR079336A1 (es) | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) | |
| EA201592006A1 (ru) | Новые биспецифические связывающие молекулы с противоопухолевой активностью | |
| PE20241349A1 (es) | Anticuerpos de union a cd3 | |
| CO6700829A2 (es) | Moduladores novedosos y métodos de uso | |
| AR091069A1 (es) | Proteinas de union a antigeno dirigidas contra el receptor st2 | |
| AR109264A1 (es) | Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
| ES2621874T3 (es) | Anticuerpos para MUC16 y métodos de uso de los mismos | |
| CO6331346A2 (es) | Anticuerpos anti-factor d humanizados, secuencias, composiciones, kit y articulo de fabricacion del mismo | |
| NZ604360A (en) | Il-1 binding proteins | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| MX2022000081A (es) | Proteínas de unión al antígeno anti carcinoma de células escamosas esofágico 1 de nueva york (ny-eso-1) y métodos de uso. | |
| ECSP18084153A (es) | Anticuerpos anti-BASIGIN humanizados y uso de los mismos | |
| CY1106573T1 (el) | Ανοσοθεραπεια καρκινου | |
| ZA202403275B (en) | Anti-lag3 antibody, pharmaceutical composition and use |